WeChat· 智药邦·· 11 hours agoPickScore63
insitro and AstraZeneca Strike $1.46 Billion Alliance on MASH and Cardiomyopathy Targets
In brief
On October 15, 2026, AI drug discovery company insitro entered a global exclusive research collaboration with AstraZeneca worth about $1.46 billion, focused on discovering new targets and therapies for MASH and cardiomyopathy. insitro will use its Virtual Human platform to identify causal biology in both diseases and advance AstraZeneca-nominated targets from discovery to preclinical candidate; AstraZeneca will lead all clinical development, regulatory filings, and commercialization.
Why it matters
Reports a large AI drug discovery collaboration between insitro and AstraZeneca.
Source: WeChat · mp.weixin.qq.com